(Q36373455)

13 August 2017

Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations (English)

1 reference

13 August 2017

0 references

Gurjit Khurana Hershey

12

object named as

Gurjit K Khurana Hershey

1 reference

13 August 2017

Alkis Togias

3

0 references

Robyn T Cohen

object named as

Robyn T Cohen

9

0 references

Stanley J Szefler

20

object named as

Stanley J Szefler

1 reference

13 August 2017

19

William W Busse

1 reference

13 August 2017

13

Rebecca S Gruchalla

1 reference

13 August 2017

16

Meyer Kattan

1 reference

13 August 2017

18

James E Gern

1 reference

13 August 2017

Stephen J Teach

1

1 reference

13 August 2017

Michelle A Gill

2

1 reference

13 August 2017

Christine A Sorkness

4

1 reference

13 August 2017

Samuel J Arbes

5

1 reference

13 August 2017

Agustin Calatroni

6

1 reference

13 August 2017

Jeremy J Wildfire

7

1 reference

13 August 2017

Peter J Gergen

8

1 reference

13 August 2017

Jacqueline A Pongracic

10

1 reference

13 August 2017

Carolyn M Kercsmar

11

1 reference

13 August 2017

Andrew H Liu

14

1 reference

13 August 2017

Edward M Zoratti

15

1 reference

13 August 2017

Kristine A Grindle

17

1 reference

13 August 2017

language of work or name

English

0 references

publication date

23 October 2015

1 reference

The Journal of Allergy and Clinical Immunology

13 August 2017

1 reference

13 August 2017

136

1 reference

13 August 2017

6

1 reference

13 August 2017

1476-1485

1 reference

Seasonal risk factors for asthma exacerbations among inner-city children

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Improved molecular typing assay for rhinovirus species A, B, and C.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

High titers of IgE antibody to dust mite allergen and risk for wheezing among asthmatic children infected with rhinovirus

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Asthma outcomes: exacerbations

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Asthma exacerbations: origin, effect, and prevention.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

A trial of clarithromycin for the treatment of suboptimally controlled asthma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Role of viral respiratory infections in asthma and asthma exacerbations

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Counterregulation between the FcepsilonRI pathway and antiviral responses in human plasmacytoid dendritic cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Mepolizumab and exacerbations of refractory eosinophilic asthma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Systematic review of the dose-response relation of inhaled fluticasone propionate.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Potential adverse effects of the inhaled corticosteroids

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

The Back to School asthma study: the effect of montelukast on asthma burden when initiated prophylactically at the start of the school year

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trial.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Statistics in medicine--reporting of subgroup analyses in clinical trials.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Severe exacerbations predict excess lung function decline in asthma.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

The September epidemic of asthma exacerbations in children: a search for etiology

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

Deficient antiviral immune responses in childhood: Distinct roles of atopy and asthma

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4679705

10.1016/J.JACI.2015.09.008

5 December 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

26518090

1 reference